Rafael Holdings shares plunge 37.89% after Phase 3 NPC trial misses primary endpoint
AI Summary- Rafael Holdings shared Phase 3 TransportNPC findings from Cyclo Therapeutics' Trappsol Cyclo study.
- Trappsol Cyclo slowed progression 64% at Week 96 overall and 71% in a prespecified subgroup.
- Rafael expects a New Drug Application submission in Q4 2026 after an FDA pre-NDA meeting.